Results for
""Proto-Oncogene Proteins c-raf""[mesh_terms]

Molecular regulation of cholesterol biosynthesis: implications in carcinogenesis.

R P Singh, Raj Kumar, Nidhi Kapur

Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer 2003;22(2):75-92

Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006.

S Seeber, S Kredtke, M E Scheulen, D Strumberg, R A Hilger

International journal of clinical pharmacology and therapeutics 2005;42(11):648-9

Massive sequence perturbation of the Raf ras binding domain reveals relationships between sequence conservation, secondary structure propensity, hydrophobic core organization and stability.

F-X Campbell-Valois, Kirill Tarassov, S W Michnick

Journal of molecular biology 2006;362(1):151-71

The novel RAF1 mutation p.(Gly361Ala) located outside the kinase domain of the CR3 region in two patients with Noonan syndrome, including one with a rare brain tumor.

Frederike L Harms, Malik Alawi, David J Amor, Tiong Y Tan, Goran Cuturilo, Christina Lissewski, Julia Brinkmann, Denny Schanze, Kerstin Kutsche, Martin Zenker

American journal of medical genetics. Part A 2019;176(2):470-476

Cytosolic glucocorticoid receptor-interacting proteins.

A C Wikström, C Widén, A Erlandsson, E Hedman, J Zilliacus

Ernst Schering Research Foundation workshop 2003

Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory Melanoma or Other Solid Tumors With BRAF Fusions or CRAF/RAF1 Fusions or Amplification: Phase II FIRELIGHT-1 Substudy.

Maria Vieito, Elena Garralda Cabanas, Inderjit Mehmi, Caroline Gaudy-Marqueste, Bert H O'Neil, Theresa M Medina, Amy L Body, Ana Arance, Shivaani Kummar, Yana G Najjar, Philippe L Bedard, Andrew Rankin, Caroline Chu, Chris McKenna, Stephanie Hume, Lisa M Kopp, Jeeyun Lee

JCO precision oncology 2026;10(10):e2501187

Development of fluorizoline analogues as prohibitin ligands that modulate C-RAF signaling, p21 expression and melanogenesis.

Nora Chouha, Hussein Abou-Hamdan, Hajime Yurugi, Riku Yoshii, Hiromi Ii, Ahmad Najem, Ghanem E Ghanem, Susumu Nakata, Krishnaraj Rajalingam, Yu Peng, Dong Wang, Canan G Nebigil, Laurent Désaubry

European journal of medicinal chemistry 2022;242():114635

Development of a yeast protein fragment complementation assay (PCA) system using dihydrofolate reductase (DHFR) with specific additives.

Seiji Shibasaki, Kozue Sakata, Jun Ishii, Akihiko Kondo, Mitsuyoshi Ueda

Applied microbiology and biotechnology 2008;80(4):735-43

Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.

K Mross, S Steinbild, F Baas, M Reil, P Buss, S Mersmann, D Voliotis, B Schwartz, E Brendel

International journal of clinical pharmacology and therapeutics 2004;41(12):618-9

Activity of the Raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors.

Clinical colorectal cancer 2003;3(1):16-8

Candida albicans primes TLR cytokine responses through a Dectin-1/Raf-1-mediated pathway.

Daniela C Ifrim, Leo A B Joosten, Bart-Jan Kullberg, Liesbeth Jacobs, Trees Jansen, David L Williams, Neil A R Gow, Jos W M van der Meer, Mihai G Netea, Jessica Quintin

Journal of immunology (Baltimore, Md. : 1950) 2013;190(8):4129-35

Bioinformatic and experimental data decipher the pharmacological targets and mechanisms of plumbagin against hepatocellular carcinoma.

Rui Zhou, Ka Wu, Min Su, Rong Li

Environmental toxicology and pharmacology 2020;70():103200

Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.

Yafei Li, Zhifu Sun, Julie M Cunningham, Marie C Aubry, Jason A Wampfler, Gary A Croghan, Cassandra Johnson, Danli Wu, Jeremiah A Aakre, Julian Molina, Liewei Wang, V Shane Pankratz, Ping Yang

Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(11):3830-40

Switching on kinases: oncogenic activation of BRAF and the PDGFR family.

Nick J Dibb, Stephen M Dilworth, Clifford D Mol

Nature reviews. Cancer 2004;4(9):718-27

Molecular targeting for treatment of advanced hepatocellular carcinoma.

Il Han Song

The Korean journal of hepatology 2010;15(3):299-308